- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00872053
Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis
September 18, 2013 updated by: US Department of Veterans Affairs
The primary aim of this study is to:
- Collect pilot data on the effect of task-specific lower extremity training using the Anklebot on subjects with Multiple Sclerosis (MS) and who have foot drop;
- Collect pilot data on the use of combination therapy on improving gait in subjects with MS. This therapy will use both Anklebot training and robot-assisted gait training.
Hypothesis: Both trainings will result in improved walking performance, but the combination therapy will result in greater gains than ankle training alone.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02908-4799
- Providence VA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of MS by McDonald criteria (McDonald, Compston et al. 2001). EDSS level between 3.5-5.5, who report ambulation problems.
- Presence of unilateral foot drop that is clinically apparent to the PI or PI designate.
- Must be able to ambulate 25 feet without an assisting device.
Exclusion Criteria:
- Cardiovascular: recent MI < 4 wk, uncontrolled HTN >190/110 mmHg.
- History of uncontrolled diabetes.
- Symptoms of orthostasis when standing up.
- Circulatory problems, history of vascular claudication or pitting edema.
- Unable to fully understand instructions in order to use the equipment or the process of the study.
- Body weight over 150 kg.
- Lower extremity injuries that limit range of motion or function.
- Joint problems (hip or leg) that limit range of motion or cause pain with movement despite treatment.
- Unstable fractures.
- Pressure sores with any skin breakdown in areas in contact with the body harness or Lokomat apparatus.
- Chronic and ongoing alcohol or drug abuse.
- Pre-morbid, ongoing depression or psychosis.
- Ongoing physical therapy.
- Pregnancy (self-reported)
- PI's determination of inability to complete the test protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1
Focused Ankle Training
|
The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1).
As the participant goes through a series of ankle-training "games," the Anklebot can assist ankle movement throughout 3 planes.
|
EXPERIMENTAL: Arm 2
Combination Therapy
|
The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1).
As the participant goes through a series of ankle-training "games," the Anklebot can assist ankle movement throughout 3 planes.
The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill.
Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ankle accuracy and stiffness
Time Frame: At inclusion, after 8 sessions, after 16 sessions
|
At inclusion, after 8 sessions, after 16 sessions
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Gait assessments (e.g., 6-Minute Walk, Timed 25-Foot Walk)
Time Frame: At inclusion, after every 4 sessions
|
At inclusion, after every 4 sessions
|
Functional assessments (EDSS, MS Functional Composite)
Time Frame: At inclusion, after 8 sessions, after 16 sessions
|
At inclusion, after 8 sessions, after 16 sessions
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (ACTUAL)
December 1, 2009
Study Completion (ACTUAL)
January 1, 2010
Study Registration Dates
First Submitted
March 27, 2009
First Submitted That Met QC Criteria
March 27, 2009
First Posted (ESTIMATE)
March 31, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
September 20, 2013
Last Update Submitted That Met QC Criteria
September 18, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neuromuscular Diseases
- Mononeuropathies
- Peripheral Nervous System Diseases
- Multiple Sclerosis
- Sclerosis
- Peroneal Neuropathies
Other Study ID Numbers
- B4125K-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MS (Multiple Sclerosis)
-
Association de Recherche Bibliographique pour les...Centre Hospitalier Universitaire de Nice; Centre Hospitalier Princesse GraceCompletedHealthy | Clinically Isolated Syndrome | Multiple Sclerosis (MS) | Radiologically Isolated Syndrome | Multiple Sclerosis (MS) Relapsing Remitting | Multiple Sclerosis (MS) Primary Progressive | Multiple Sclerosis (MS) Secondary ProgressiveMonaco
-
GeNeuro Innovation SASCompletedMultiple Sclerosis (MS) | Clinically Isolated Syndrome (CIS) | Secondary Progressive MS | Primary Progressive MS | Relapsing-Remitting MSFrance, Spain, Switzerland
-
Dimitrios KarussisCompletedMultiple Sclerosis (MS)Israel
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
Anokion SAActive, not recruitingRelapsing Remitting Multiple Sclerosis | Multiple Sclerosis (MS)United States
-
University Hospital, Basel, SwitzerlandFreie Akademische Gesellschaft BaselRecruitingMultiple Sclerosis (MS)Switzerland
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedMultiple Sclerosis (MS)United States, Lebanon, Spain, Sweden, Poland, Italy, Estonia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Korea, Republic of, Lithuania, Norway, Portugal, Romania, Russian Federation and more
-
Nermin ÇalışırBursa Sevket Yilmaz Training and Research HospitalActive, not recruitingMS (Multiple Sclerosis)Turkey
-
Fondazione Italiana Sclerosi MultiplaOpera CRO, a TIGERMED Group CompanyUnknownMS (Multiple Sclerosis)Italy, Romania
-
Assistance Publique - Hôpitaux de ParisUnknownMultiple Sclerosis (MS)France
Clinical Trials on Anklebot
-
US Department of Veterans AffairsTerminated
-
VA Office of Research and DevelopmentUniversity of MarylandCompletedCerebral StrokeUnited States
-
Northwell HealthCompleted
-
VA Office of Research and DevelopmentCompleted